trending Market Intelligence /marketintelligence/en/news-insights/trending/cyScBo2vu8fs3Lhjpbkhvg2 content esgSubNav
In This List

Turning Point Therapeutics prices $202.5M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Turning Point Therapeutics prices $202.5M common stock offering

Turning Point Therapeutics Inc. priced a public offering of 4.5 million common shares at $45 apiece.

The San Diego-based clinical-stage precision oncology company is also offering underwriters the option to buy up to an additional 675,000 common shares to cover any overallotments.

Turning Point Therapeutics expects gross proceeds of $202.5 million.

The offering is expected to close Sept. 10.

Goldman Sachs & Co. LLC and SVB Leerink are the joint book-running managers for the offering. Guggenheim Securities and Wedbush PacGrow are acting as lead managers.